A detailed history of Caption Management, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Caption Management, LLC holds 30,000 shares of DNLI stock, worth $478,500. This represents 0.01% of its overall portfolio holdings.

Number of Shares
30,000
Holding current value
$478,500
% of portfolio
0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$20.24 - $31.58 $402,775 - $628,442
19,900 New
19,900 $405,000
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $48,600 - $69,540
3,000 New
3,000 $64,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.14B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.